Vivos Therapeutics (VVOS) Gross Profit (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Gross Profit data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Gross Profit rose 102.72% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (up 40.78% YoY) and the FY2025 annual result came in at $10.5 million, up 16.89% from the prior year.
• Gross Profit climbed to $3.1 million in Q1 2026 per VVOS's latest filing, from $3.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $3.9 million in Q3 2025 and bottomed at $1.5 million in Q1 2025.
• The 5-year median for Gross Profit is $2.3 million (2023), against an average of $2.4 million.
• The widest annual swing landed in 2023, when Gross Profit sank 30.01%; it then surged 102.72% in 2026.
• Tracing VVOS's Gross Profit over 5 years: stood at $2.4 million in 2022, then decreased by 12.37% to $2.1 million in 2023, then climbed by 0.38% to $2.1 million in 2024, then surged by 42.49% to $3.0 million in 2025, then gained by 2.38% to $3.1 million in 2026.
• Per Business Quant, the three latest VVOS Gross Profit figures stand at $3.1 million (Q1 2026), $3.0 million (Q4 2025), and $3.9 million (Q3 2025).

Peer Comparison